EU pharmacovigilance fee proposal trumps agency remuneration puzzle
This article was originally published in Scrip
Executive Summary
It looks as if the European Medicines Agency will have to wait for a while yet before it can turn its full attention to the thorny question of how national agencies should be remunerated for their work on behalf of the EU drug regulatory system.